- Home
- VIR
as 04-11-2025 4:00pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 724.1M | IPO Year: | 2019 |
| Target Price: | $35.67 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.95 - $14.45 | Next Earning Date: | 05-01-2025 |
| Revenue: | $74,205,000 | Revenue Growth: | -13.89% |
| Revenue Growth (this year): | -63.21% | Revenue Growth (next year): | 17.69% |
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| De Backer Marianne | VIR | Chief Executive Officer | Apr 3 '25 | Sell | $5.95 | 79,712 | $474,238.57 | 769,505 | |
| de Verneuil Vanina | VIR | EVP and General Counsel | Feb 26 '25 | Sell | $9.14 | 7,373 | $67,402.49 | 79,460 | |
| SCANGOS GEORGE A | VIR | Director | Feb 24 '25 | Sell | $9.45 | 10,056 | $95,063.39 | 698,239 | |
| HANLY ANN M. | VIR | EVP & Chief Technology Officer | Feb 24 '25 | Sell | $9.45 | 14,168 | $133,935.77 | 117,901 | |
| De Backer Marianne | VIR | Chief Executive Officer | Feb 22 '25 | Sell | $9.45 | 16,122 | $152,407.71 | 769,505 | |
| de Verneuil Vanina | VIR | EVP and General Counsel | Feb 22 '25 | Sell | $9.45 | 5,140 | $48,590.48 | 79,460 | |
| Sabatini Brent | VIR | SVP, Chief Accounting Officer | Feb 22 '25 | Sell | $9.45 | 1,562 | $14,766.21 | 46,627 | |
| SCANGOS GEORGE A | VIR | Director | Feb 18 '25 | Sell | $9.81 | 10,964 | $107,575.48 | 698,239 | |
| Sabatini Brent | VIR | SVP, Chief Accounting Officer | Feb 13 '25 | Sell | $9.15 | 1,562 | $14,291.36 | 46,627 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple
Argus Research
5 days ago
VIR: Rating increased to a BUY
Argus Research
12 days ago
VIR: Lowering target price to $6.00
Simply Wall St.
17 days ago
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company
Business Wire
a month ago
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
Argus Research
a month ago
VIR: Lowering target price to $9.00
Simply Wall St.
a month ago
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Thomson Reuters StreetEvents
a month ago
Q4 2024 Vir Biotechnology Inc Earnings Call
Compare VIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.